44.71 USD
▲-0.05+16.48%
盘后 39.13 +1.94%
2026-08-03
市值
$4.81B
市盈率
—
EPS
-1.66
股息率
—
52 周区间
12.30 – 48.40
成交量
4.19M
Beta
0.33
目标价
49.92
52W 低 12.3052W 高 48.40
价格走势
公司简介
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical tr...